MedTrace Logo

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

NCT01537497 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2012-07-10

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate pharmacodynamics of single oral doses of PF-05175157 in a dose-dependent fashion in healthy volunteers

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

PF-05175157

One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.

DRUG

PF-05175157

One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.

DRUG

PF-05175157

One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.

DRUG

Placebo

One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01537497 on ClinicalTrials.gov